New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
06:33 EDTALXNAlexion's Soliris approved by FDA from accelerated to regular approval
Alexionís supplemental Biologics License Application providing regular approval for Soliris for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy has been approved by the FDA. This update reflects Alexionís fulfillment of post-marketing requirements, including the submission of confirmatory data from two additional prospective clinical trials, including one in pediatric patients with aHUS. The revised label now specifies important longer-term clinical benefit associated with chronic and sustained Soliris treatment with inclusion of results with two years of ongoing treatment in aHUS patients. The updated label also includes data on the use of Soliris treatment prior to use of supportive care with either plasma exchange or plasma in prospective clinical trials.
News For ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
10:56 EDTALXNOptions with increasing implied volatility
Subscribe for More Information
10:10 EDTALXNAnalyst calls sharp pullback in biotech stocks 'misguided'
Subscribe for More Information
06:45 EDTALXNBiotech valuation concerns 'misguided,' says Piper Jaffray
Subscribe for More Information
March 25, 2015
08:57 EDTALXNAlexion has a conference call hosted by JPMorgan
Subscribe for More Information
March 23, 2015
07:23 EDTALXNAlexion management to meet with UBS
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use